Calcineurin inhibitors in heart transplantation

Transplantation Proceedings

Volumn 37, Issue 9, 2005, Pages 4018-4020

  Crespo Leiro, M G ^a,b  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; STEROID; TACROLIMUS;

CARDIAC ALLOGRAFT VASCULOPATHY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DRUG EFFICACY; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; MAINTENANCE THERAPY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZATION;

CALCINEURIN; CYCLOSPORINE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; TACROLIMUS;

EID: 29544435523     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2005.09.155     Document Type: Conference Paper

References (18)

1. P. Halloran Immunosuppressive drugs for kidney transplantation N Engl J Med 351 2004 2715
2. D. Taylor Cardiac transplantation drug regimens for the 21st century Ann Thorac Surg 75 2003 S72
3. J. Borel, C. Feurer, H. Gubler Biological effects of cyclosporin A a new antilymphocytic agent Agent Actions 6 1976 468
4. M. Stalder, T. Birsan, R. Hubble In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates J Heart Lung Transplant 22 2003 1343
5. T. Goto, T. Kino, H. Hatanaka Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis Transplant Proc 19 1987 4
6. T. Goto, T. Kino, H. Hatanaka FK506 historical perspectives Transplant Proc 23 1991 2713
7. J. Lindenfeld, G. Miller, S. Shakar Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs Circulation 110 2004 3734
8. D. Taylor, M. Barr, B. Meiser Suggested guidelines for the use of tacrolimus in cardiac transplantation J Heart Lung Transplant 20 2001 734
9. H. Valantine Neoral use in the cardiac transplant recipient Transplant Proc 32 2000 27S
10. G.E. Sarris, K.A. Moore, J.S. Schroeder Cardiac transplantation the Stanford experience in the cyclosporine era J Thorac Cardiovasc Surg 108 1994 240
11. R. Robbins, C. Barlow, P. Oyer Thirty years of cardiac transplantation at Stanford university J Thorac Cardiovasc Surg 117 1999 939
12. H. Eisen, R. Hobbs, S. Davis Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients arandomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine - results at 24 months after transplantation Transplantation 71 2001 70
13. B. Reichart, B. Meiser, M. Vigano European multicenter tacrolimus heart pilot study three year follow-up J Heart Lung Transplant 20 2001 249
14. D. Taylor, M. Barr, B. Radovancevic A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation decreased hyperlipidemia and hypertension with tacrolimus J Heart Lung Transplant 18 1999 336
15. M. Rinaldi, M. Grimm, N. Yonan European Tacrolimus Heart Study Group Risk/benefit evaluation of tacrolimus (TAC) vs. cyclosporine microemulsion (CsA) after cardiac transplantation 18-month results J Heart Lung Transplant 23 suppl2S 2004 S45
16. A. Keogh Calcineurin inhibitors in heart transplantation J Heart Lung Transplant 23 2004 S202
17. H. Eisen, E. Tuzcu, R. Dorent Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplants recipients N Engl J Med 349 2003 847
18. A. Keogh, M. Richardson, P. Ruygrok Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years a randomized clinical trial Circulation 110 2004 2694